The Guardian
Email YouTube Facebook Instagram Twitter

Shareholders task Neimeth on WHO certification, performance

Related

SHAREHOLDERS of Neimeth Pharmaceuticals Plc have urged the management of the company to ensure that it obtained the World Health Organization (WHO) certification to enhance profitability and increase shareholders’ value.

The shareholders spoke at the 56th yearly general meeting of the company in Lagos, explaining that this would ensure the products’ international acceptance, as well as offer the company the needed turnaround.

Specifically, the President, Independent Shareholders Association of Nigeria, Sir Sunny Nwosu, argued that the company needed to stay ahead of competitions and in line with trends to remain within the business environment.

He said this has become imperative because the country’s pharmaceutical industry is becoming saturated.

Nwosu also expressed the need for the company to focus more on the production of antibiotics, adding that it would enhance growth and increase its market share in the industry.

The National Cordinator, Progressive Shareholders Association of Nigeria, Boniface Okezie, also commended the company’s board for its operational efficiencies despite huge investments the company made recently on the installation of new machineries for production.

He however, advised the company to embark on aggressive marketing campaign to attract more patronage for the new products on malaria and hypertension.

The Managing Director of the company, Emmanuel Ekunno, assured shareholders that the company has concluded plans to roll out products that would reposition the company for profitability and price competitiveness.

He explained that the company has established strong marketing footprint that would propel a sustained organic growth in 2015.



No Comments yet